Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$3.80 target
Investment Highlights
• Quality product will likely appeal to patients. We believe Emblem is positioned for faster growth through its GrowWise clinics. Further, we believe Emblem’s high-quality product is likely to provide more consistent medical benefit to these ‘sticky’ customers.
• Novel formulations could command premium pricing. We believe that Emblem’s pharma strategy is a key differentiator. Improved convenience and tighter dosing is likely to reduce the amount of drug required and increase patient compliance; as a result, we believe that Emblem could achieve substantially higher pricing.
• Medical creates a strong foundation for our valuation. We believe Emblem’s medical focus suggests a more stable foundation to our valuation. Because the medical cannabis market already exists, we see lower risk to the company’s projected cash flows. Based on our DCF analysis, we value this business alone at $3.28 per share.
Valuation
We value the medical cannabis market based on a DCF model, using a 16.0% WACC and 3.0% terminal growth: the higher-risk rec opportunity is valued using a probability-weighted NPV. Despite the miss, our target price remains C$3.80 as Emblem’s projected peak capacity and pharmaceutical strategy remains intact. Our target represents a 55.1% projected annualized return and supports our SPECULATIVE BUY rating.
Emblem trades at 9.7x its projected funded capacity, compared to peers at 8.4x. However, we believe Emblem’s medical focus, product mix, and premium pricing support a higher multiple. Although the company is awaiting Health Canada approval to sell cannabis oil, we believe this could be a significant catalyst for investors in the near term.
who could canopy acquire in this environment?
i went to a Dundee Conference and he said if I could clone anyone in this industry it would be John Stewart @ Emblem.....maybe he more than clones him lol
DDD.H turning into a major Argentinian silver miner - 80M Oz Ag and 700,000 oz Au. no one looking
Helius Medical (hsm-canada) hsdt - US
hell of a story. Just financed for $7 million @ .96 US.
Risk/reward for a medical device company looks real good.
What other company in the sector can raise $3 million.
Extremely cheap at these prices.
Organigram Holdings Inc. has closed its previously announced non-brokered $3-million financing.
The first $1,000,000 of the Financing has been received from Duce Holdings, LLC ("Duce") and Denaco Group Ltd., a corporation in which Denis Arsenault, the Chief Executive Officer of the Company, is a director ("Denaco"). In exchange, Duce and Denaco have been issued subordinated secured debentures (the "Debentures") and 200,000 common share purchase warrants of the Company (the "Warrants").
The Debentures shall bear interest at 9% per annum and shall mature on September 1, 2017; the Debentures are secured with a subordinated charge over all of the Company's assets. The Debentures may be converted into common shares of the Company in certain limited circumstances. Each whole Warrant entitles the holder thereof to purchase one common share of the Company for $0.45 (subject to TSX-V pricing guidelines). The Warrants shall not be exercisable before 12 months after the Closing Date and shall expire on June 15, 2017.
Neither the Debentures nor the Warrants are transferable, and any shares issued in connection with the exercise of Warrants or conversion of the Debentures, if any, will be subject to a four month hold period expiring on January 1, 2016, in accordance with the policies of the TSX Venture Exchange and applicable securities laws.
The Company also received $2,000,000 from Farm Credit Canada in the form of a secured long term loan facility, with an initial advancement of $1,000,000 on August 31, 2015 and the remaining $1,000,000 to be received by the Company in tiered disbursements.
"As I have mentioned before, this funding represents a sign of ongoing success for the company and the leadership of our management team," said Roger Rogers, President and CFO. "This funding permits us to grow that success through our operations and facility in Moncton, which in turn boosts our ability to offer quality medical products to our clients. This begins Q1 of our new fiscal year, which began on September 1st, 2015, on a high note and I look forward to Organigram's continued success."
and I think the lawsuit is completely frivolous, however the mkt doesn't have clarity.
huge for Organigram and the sector. finally realizing health Canada allowed very few companies to sell undermining their plan. I guess they are putting their foot down. mmpr co's should thrive
Some dispensaries selling medical cannabis were reportedly sent a letter via email today from Health Canada warning them to immediately suspend their activities that are in violation of Federal law.
OGRMF
Some dispensaries selling medical cannabis were reportedly sent a letter via email today from Health Canada warning them to immediately suspend their activities that are in violation of Federal law.
Organigram is the best of the others. should move
Organigram on radar
At this mkt cap i think its easily the cheapest and best value for investment dollars if you buy into the mmpr pemise. Big tobacco will eventually take this company over
Rough Quarter. One of Canada's top commentators on the sector makes top pick. is this Tweed?
http://www.mmprinvestments.com/deal/
Top name in the Sector:
http://www.mmprinvestments.com/deal/
wow! takes care of patient acquisition strategy. revenue model is clear. game changer
OrganiGram to supply pot to Trauma Healing patients
2014-11-10 08:08 ET - News Release
ORGANIGRAM SIGNS LETTER OF INTENT WITH TRAUMA HEALING CENTERS
OrganiGram Holdings Inc., through its wholly owned subsidiary, Organigram Inc., has entered into a binding letter of intent with Trauma Healing Centers Inc. pursuant to which OrganiGram will be the preferred supplier of medical marijuana to Trauma Healing Centers' patients.
Under the terms of the LOI, OrganiGram will produce the specified strains of medical marijuana requested by Trauma Healing Centers to treat its patients suffering from Post-Traumatic Stress Disorder ("PTSD"). The LOI commits OrganiGram to provide up to 1,500 kilograms of medical marijuana specifically for Trauma Healing Centers' patients in 2015, increasing to 3,000 kilograms in 2016 and by 20% each year thereafter. The LOI covers a term of 10 years with an option to extend by 5 years at the end of the initial term.
In addition, OrganiGram has agreed to collaborate with Trauma Healing Centers to conduct research related to PTSD and the use of medical marijuana for treatment.
"We are extremely happy to finally be cementing this long-term relationship with Trauma Healing Centers. The services Trauma Healing Centers provides to Canadian Veterans and First Responders is extremely important and we are proud to be in a position to assist in their mission." said Denis Arsenault, Chairman & CEO of OrganiGram.
Trauma Healing Centers is in the process of opening 13 centers across Canada. The first 4 centers are scheduled to open in Edmonton, Ottawa, Quebec and Halifax Region in January 2015. An additional 9 centers are scheduled to open across Canada by June 2015.
"Securing a consistent supply of the highest quality medicine for our patients is a vital part to the services we provide at Trauma Healing Centers. We are pleased that OrganiGram has guaranteed an ongoing supply of medicine for our patients and we look forward to a long and successful partnership." said Kyle Atkinson, President of Trauma Healing Centers.
there are only 2 names to look at Tweed and OrganiGram - Significant First mover advantage - Research Report
http://www.cantechletter.com/2014/09/industry-insight-medical-marijuana/
ORGANIGRAM TO INCREASE GROWING CAPACITY BY 500% OVER NEXT 4 MONTHS
Moncton, N.B. September 10, 2014 – OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (the “Company”) is pleased to provide an update on the expansion currently underway at its Medical Marijuana facility in Moncton, NB.
On July 14th, the Company began construction on three additional grow rooms, each of which will consist of 72 flowering lights. These rooms are expected to begin production on October 15th, 2014. Additionally, the company will begin construction of a further 9 flowering rooms on October 1st, 2014. These 72 flowering light rooms are expected to begin producing in December 2014.
Once completed, this phase of expansion will add 12 grow rooms totaling 864 flowering lights to the current facility. This increase will represent an additional 3,000kg of production per year, which represents an annual revenue increase of $21,000,000.
CEO Denis Arsenault states, “This is a very exciting time for Organigram and all of our shareholders. This is the first stage of a multi-stage expansion plan and we are very pleased with the speed at which we have been able to execute.”
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company who’s wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
Substantial blue sky growth ahead Very nice
ORGANIGRAM TO INCREASE GROWING CAPACITY BY 500% OVER NEXT 4 MONTHS
Moncton, N.B. September 10, 2014 – OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (the “Company”) is pleased to provide an update on the expansion currently underway at its Medical Marijuana facility in Moncton, NB.
On July 14th, the Company began construction on three additional grow rooms, each of which will consist of 72 flowering lights. These rooms are expected to begin production on October 15th, 2014. Additionally, the company will begin construction of a further 9 flowering rooms on October 1st, 2014. These 72 flowering light rooms are expected to begin producing in December 2014.
Once completed, this phase of expansion will add 12 grow rooms totaling 864 flowering lights to the current facility. This increase will represent an additional 3,000kg of production per year, which represents an annual revenue increase of $21,000,000.
CEO Denis Arsenault states, “This is a very exciting time for Organigram and all of our shareholders. This is the first stage of a multi-stage expansion plan and we are very pleased with the speed at which we have been able to execute.”
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company who’s wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
2nd licensed producer follows tweed in IPO
Please visit the website @ www.organigram.ca to learn about the Company and click on the link for the Investor Presentation:
http://fjet.ca/sites/default/files/Organigram_Investor_Presentation.pdf
OrganiGram is the only fully bilingual licensed producer with high-quality, organic, condition-specific medical marijuana. With no synthetic nutrients, pesticides, herbicides or additives of any kind, the company’s 100% organic products come in five different strains for various objectives, ranging from appetite stimulation for cancer patients to managing chronic pain for arthritis sufferers.
The team’s focus on producing high-quality organic products sets it apart from many other licensed producers and aspiring licensed producers. In many cases, these companies lack significant growing expertise and are more focused on maximizing near-term profits than establishing an infrastructure to create high-quality products that have the potential to capture greater market share.
Management plans to expand its operations to generate more than $30 million in sales and create 40 more jobs by next summer.
Businesses say while pot still has a stigma, that image is changing in Canada and appeals to U.S. and global investors because of its federally regulated program and contrasts with the United States, where medical marijuana is illegal at the national level. The market is expected to generate $3.4 billion a year in taxable sales over the next decade, according to government estimates.
"The investment community is seeing Canada as a safe place to invest due to the regulatory framework," said Chief Executive Denis Arsenault, noting the firm had seen "tremendous" interest from U.S. and Canadian funds.
The company, which received its license in March, began production later in the month and will start shipping the product next week. It has more than 1,000 patients on the waiting list to receive the drug.
OrganiGram has raised $10.6-million so far, and its latest financing this month was oversubscribed by four times, Arsenault said. The company was valued at $36-million based on the recent round.
OrganiGram is listed under the ticker “OGI” in Canada and OGRMF in the US.
OrganiGram IPO's
Please visit the website @ www.organigram.ca to learn about the Company and click on the link for the Investor Presentation:
http://fjet.ca/sites/default/files/Organigram_Investor_Presentation.pdf
OrganiGram is the only fully bilingual licensed producer with high-quality, organic, condition-specific medical marijuana. With no synthetic nutrients, pesticides, herbicides or additives of any kind, the company’s 100% organic products come in five different strains for various objectives, ranging from appetite stimulation for cancer patients to managing chronic pain for arthritis sufferers.
The team’s focus on producing high-quality organic products sets it apart from many other licensed producers and aspiring licensed producers. In many cases, these companies lack significant growing expertise and are more focused on maximizing near-term profits than establishing an infrastructure to create high-quality products that have the potential to capture greater market share.
Management plans to expand its operations to generate more than $30 million in sales and create 40 more jobs by next summer.
Businesses say while pot still has a stigma, that image is changing in Canada and appeals to U.S. and global investors because of its federally regulated program and contrasts with the United States, where medical marijuana is illegal at the national level. The market is expected to generate $3.4 billion a year in taxable sales over the next decade, according to government estimates.
"The investment community is seeing Canada as a safe place to invest due to the regulatory framework," said Chief Executive Denis Arsenault, noting the firm had seen "tremendous" interest from U.S. and Canadian funds.
The company, which received its license in March, began production later in the month and will start shipping the product next week. It has more than 1,000 patients on the waiting list to receive the drug.
OrganiGram has raised $10.6-million so far, and its latest financing this month was oversubscribed by four times, Arsenault said. The company was valued at $36-million based on the recent round.
OrganiGram is listed under the ticker “OGI” in Canada and OGRMF in the US.
OrganiGram IPO's Monday the 25th under OGI in Canada
http://www.theglobeandmail.com/report-on-business/medical-marijuana-producer-organigram-set-to-go-public-monday/article20180442/
OrganiGram IPO's Monday the 25th under OGI
http://www.theglobeandmail.com/report-on-business/medical-marijuana-producer-organigram-set-to-go-public-monday/article20180442/
2nd Canadian licensed producer set to go public under ticker OGI on TSX
Canadian medical marijuana company OrganiGram set to go public
22-Aug-2014 17:36
By John Tilak
TORONTO, Aug 22 (Reuters) - Canadian medical marijuana producer OrganiGram Inc is set to go public on Monday, its chief executive said, the second such firm to list on the venture exchange next week, highlighting investor appetite for a high-growth industry.
OrganiGram and Bedrocan Cannabis Corp both plan to list on Aug. 25. The two firms, via reverse takeovers, will join Tweed Marijuana Inc TWD.V on the TSX Venture Exchange giving investors in public markets three licensed producers to choose from. Tweed went public in April and is valued at C$100.8 million ($92.11 million). (Full Story)
Canada appeals to U.S. and global investors because of its federally regulated program and contrasts with the United States, where medical marijuana is illegal at the national level. Regulator Health Canada estimates that the market will grow to C$1.3 billion over the next decade. (Full Story)
"The investment community is seeing Canada as a safe place to invest due to the regulatory framework," said Chief Executive Denis Arsenault, noting the firm had seen "tremendous" interest from U.S. and Canadian funds.
Moncton, New Brunswick-based OrganiGram wants to capture the Eastern Canadian and French-speaking markets. It has started to establish a sales force in Québec.
The company, which received its license in March, began production later in the month and will start shipping the product next week. It has more than 1,000 patients on the waiting list to receive the drug.
OrganiGram has raised C$10.6 million so far, and its latest financing this month was oversubscribed by four times, Arsenault said. The company was valued at C$36 million based on the recent round.
OrganiGram will list under the ticker symbol "OGI."
Jacob Securities and Jordan Capital Markets are providing investment banking services for the company, while McMillan and Tripp Business Law are giving legal advice.
Reverse takeovers, a method used by smaller firms to access public markets, are carried out using a shell company already listed on an exchange. They are typically faster and cheaper than traditional initial public offerings. (1 US dollar = 1.0944 Canadian dollar)
(Reporting by John Tilak; Editing by James Dalgleish) ((john.tilak@thomsonreuters.com; 1-416-687-7918; Reuters Messaging: john.tilak.reuters.com@reuters.net))
Read more at http://www.stockhouse.com/companies/bullboard/v.twd/tweed-marijuana-inc#FEcAypLbHPSV2b41.99
CA:OGI
Canadian medical marijuana company OrganiGram set to go public
22-Aug-2014 17:36
By John Tilak
TORONTO, Aug 22 (Reuters) - Canadian medical marijuana producer OrganiGram Inc is set to go public on Monday, its chief executive said, the second such firm to list on the venture exchange next week, highlighting investor appetite for a high-growth industry.
OrganiGram and Bedrocan Cannabis Corp both plan to list on Aug. 25. The two firms, via reverse takeovers, will join Tweed Marijuana Inc TWD.V on the TSX Venture Exchange giving investors in public markets three licensed producers to choose from. Tweed went public in April and is valued at C$100.8 million ($92.11 million). (Full Story)
Canada appeals to U.S. and global investors because of its federally regulated program and contrasts with the United States, where medical marijuana is illegal at the national level. Regulator Health Canada estimates that the market will grow to C$1.3 billion over the next decade. (Full Story)
"The investment community is seeing Canada as a safe place to invest due to the regulatory framework," said Chief Executive Denis Arsenault, noting the firm had seen "tremendous" interest from U.S. and Canadian funds.
Moncton, New Brunswick-based OrganiGram wants to capture the Eastern Canadian and French-speaking markets. It has started to establish a sales force in Québec.
The company, which received its license in March, began production later in the month and will start shipping the product next week. It has more than 1,000 patients on the waiting list to receive the drug.
OrganiGram has raised C$10.6 million so far, and its latest financing this month was oversubscribed by four times, Arsenault said. The company was valued at C$36 million based on the recent round.
OrganiGram will list under the ticker symbol "OGI."
Jacob Securities and Jordan Capital Markets are providing investment banking services for the company, while McMillan and Tripp Business Law are giving legal advice.
Reverse takeovers, a method used by smaller firms to access public markets, are carried out using a shell company already listed on an exchange. They are typically faster and cheaper than traditional initial public offerings. (1 US dollar = 1.0944 Canadian dollar)
(Reporting by John Tilak; Editing by James Dalgleish) ((john.tilak@thomsonreuters.com; 1-416-687-7918; Reuters Messaging: john.tilak.reuters.com@reuters.net))
Read more at http://www.stockhouse.com/companies/bullboard/v.twd/tweed-marijuana-inc#FEcAypLbHPSV2b41.99
3 billion barrel oil find in DRC
http://www.ventures-africa.com/2014/08/3bn-barrels-of-oil-discovered-in-drcongo/
Pan African Oil (PAO.ca) is right there. trading under cash with big upside
Financing?
Company needs a firm to get behind them. no takers, all retailers without revenue. They need to do a bought deal. anyone will to do a raise at $2.50?
No brainers long term
PBG-T - move has begun
PAO-tsxv - has .10 cents a share in cash. - on the prowl in Nigeria. phenomenal management
Pan African Oil - PAO-tsx
$5 million cash
Management sold last company to Gran Tira Energy (gte-nyse)
mkt cap of $ 3 million. will do something, and something really good eventually. Has explosive upside when deal announced.
Former founders of Biovail which was bought out by Valeant (vrx-nyse $131/share) is behind Trimel Pharmaceuticals (TRLPF). Apparently potential is staggering.
Been in this for 3 years. considering taking half off at the moment. Explosive move here on no news yet.....anyone know anything abut Trimel Pharmaceuticals? Biovail founders behind it. A biotech investor with a first class track record mentioned to own some within the next month. anyone else hearing anything about them?
TRLPF - otc or TRL on Canadian exchange.
well, I think it is. the no news news release means the punters will be selling as they thought it was a buy-out or as stated got the wrong titan. Expect a PP soon. wont be surprised if it trades back to where its been trading for the last 4 months @ .50 cents
Well they need money and they are still in beta testing and look to commercialize in 2015. Not sure why someone else would buy them before testing complete, FDA approval and the need for money? that being said I think a .65-.75 PP will prob be announced with this volume.
Greatest Gold Closeology i have seen in some time. Buy the explorers for signicant percent gains...
Tembo Gold (TSX-V: TEM) is a Canadian publicly listed gold exploration company focused in Tanzania on its 100% owned Tembo gold project located adjacent to the 20Moz Bulyanhulu Mine. The company has commenced a 87,000m drill program with significant initial high grade results.
Tembo Gold Investment Highlights
• HIGHLY PROSPECTIVE GOLD ASSET: Located adjacent to African Barrick's 20Moz Bulyanhulu Mine in the prolific Lake Victoria Greenstone belt, the 123km2 property has highly prospective geology, encouraging earlier exploration with promising results, and multiple targets identified
• HIGH QUALITY MANAGEMENT TEAM: CEO: David Scott, formerly of Barrick Gold’s subsidiary Kahama Mining Corporation, 32 years experience, 13 years in Tanzania; Chairman: Dave Anthony, former COO of African Barrick, 30 years experience, 10 years in Tanzania
www.tembogold.com
Stonegate Agricom - ST - Toronto.
52% owned by Sprott Resources.
huge cash position
Management previously founded Thompson Creek Mining which went to $25/share.
Buy all you can at .65.
mgmxf- magma energy - Stansberry featuring next week.
will move to $1.50.....
next pick cyref - Cirrus Energy. - trading at cash value. KNOC just goes hostile on area player Dana Pet. for 2.9 billion
CYR-TSX. Cirrus Energy
$60 million in cash
Dutch North Sea
KNOC just annouces hostile takeover bid for Dana
highly successful and technical management team.richest player in Canada owns 15 million shares and paid north of $2. Trading at cash - .60.
mgmxf -otc or mxy-tsx will fly this week. mark it. top letter writer featuring this week.
will give you the next pick next week......
The Leader in the Solar Integration Sector.
Acro Energy (ART:V) is positioning itself to become a National Brand in the Solar Integration Business.
http://www.sustainablebusiness.com/index.cfm/go/news.feature/id/1736
Acro Energy (ART:TSXV) is a California Solar Integration company.
They are now the 5th largest residential installer in California and within the top ten in the country. During the last twelve months the market in which they compete has changed dramatically, for the better:
• Panel pricing has declined by 50%. When they were bidding on jobs in the summer of ‘08 they typically bid $8 watt and fully one-half of that amount was the cost of the panel. The panel prices have dropped to the $2 range with “no-name” Chinese brands available at $1.50/watt. They expect to pay less than $1.50/watt for brand name panels (Suntech, Sharp etc) in 2010.
• They have recently signed a partnership agreement with SunRun to provide 100% financing to our customers, in any state that we chose to operate. As you could imagine, financing a solar system is the single biggest problem in the industry – problem solved on their end.
• They now have a plan to bring solar to the middle class with a product that can now be sold over the phone. 2010 is going to mark the mass adoption of solar.
• Their management team is now complete with industry leading talent http://acroenergy.com/investors/company-officers/. President, Nat Kreamer founded SunRun Solar and raised $110 million for the company, is one of the most respected names in the Solar industry.
• After a comprehensive rebranding process the management team has built a platform in operations and marketing that is ready for scale.
• Solar Panel manufacturers are looking to integrate vertically within the next eighteen to twenty-four months as their product becomes commoditized. Their targets are, and will continue to be, solar integration companies. First Solar has taken over DT Solar and invested $25 million in SolarCity. SunPower has taken over Solar Sales in Australia and Solar Solutions in Italy. LDK has recently taken an equity stake in Solar Green Technology SpA. Itochu recently purchased Solarnet and Trina, Yingli and others are all looking to take equity stakes in Solar Integrators. Solar integrators are quietly getting a lot of attention from the Panel Manufacturers, Bankers and Private Equity as they look to have the highest ROI going forward with them being natural takeovers in mind.
• Acro has a great management team (own 65% of the company - 23 million shares out), vision and operations.
A Leader in the Solar Industry
This look like the equilvalent of Atlantic, only Acro is in California, the world's largest market for Solar. They look like they could even be takeover target for AWSL.
Acro Energy (ART:TSXV) is positioning itself to become a National Brand in the Solar Integration Business.
http://www.sustainablebusiness.com/index.cfm/go/news.feature/id/1736
A Leader in the Solar Industry
Acro Energy ART:TSX) is positioning itself to become a National Brand in the Solar Integration Business.
http://www.sustainablebusiness.com/index.cfm/go/news.feature/id/1736